fibrillarin like rRNA 2'-O-methyltransferase 1Genealiases: []
Q-omics provides the consensus-scored FBLL1 profile across patient tissues and cancer cell-line models. FBLL1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FBLL1 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, FBLL1 RNA expression shows 13,018 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, THCA, and LSCC as cancer lineages where FBLL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBLL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBLL1 survival associations across molecular data types. FBLL1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBLL1 RNA expression–survival associations across cancer types. High FBLL1 expression shows unfavorable associations in LIHC, KIRC, CESC and LUSC, but favorable associations in LGG and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FBLL1 RNA expression.
This table summarizes FBLL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBLL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBLL1 shows lower tumor expression in STAD and KIRC and higher tumor expression in THCA, LUSC, LIHC and KIRP. The THCA box plot shows higher FBLL1 RNA expression in tumor versus normal tissue (log2 FC = +0.833, t-test p < 0.001).
This table shows molecular features associated with FBLL1 in patient tissues and cancer cell lines. In patient samples, FBLL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBLL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
